Wipfli Financial Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Wipfli Financial Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4K	Buy	+318	New	+$4.59K	﹤0.01%	2152

Other funds holding PMVP

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Wipfli Financial Advisors's PMVP Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in PMV Pharmaceuticals (PMVP) in Q3 2022: 318 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #2152 among its holdings.

120 funds tracked by Wall St. Rank hold PMVP as of Q3 2022.

Wipfli Financial Advisors held 318 shares of PMV Pharmaceuticals worth $4K as of Q3 2022.
PMV Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
PMV Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2152 holding.
120 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.